and 13-valent pneumococcal conjugate vaccine (PCV13) account for pneumococcal disease burdens in most developed countries of 65–85% and 80–90%, respectively. The seroprevalence of NVTs after ...

recommended the approval of CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

Based on country-level data from the following four EU countries, the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate ...

High 19A serotype prevalence is critical in the decision-making process for electing the best options for pneumococcal conjugate vaccines ... 31 In the same line, the high frequency of exclusively PCV ...

You have a good eye. This past fall, the Centers for Disease Control and Prevention changed the recommended age for getting the vaccine for pneumococcal pneumonia from those 65 and older to those ...

Several vaccinations are recommended for such patients, including the Hepatitis B vaccine, pneumococcal conjugate vaccine (PCV13), and pneumococcal polysaccharide vaccine (PPSV23). The PCV13 should be ...

JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...